A study on the neurotoxicity of broxyquinoline and brobenzoxaldine combination in therapeutic doses.
The neurotoxicity of a combination of broxyquinoline and brobenzoxaldine (Intestopan Forte, containing 500 mg and 100 mg of the drugs respectively per capsule) was investigated by prospective clinical and electrophysiological studies in patients and volunteer subjects given the drugs in therapeutic doses (two capsules three times a day for 5 days). Of 16 patients with intestinal amoebiasis given the drugs (study A), 13 (81.25%) were cured. Adverse effects were mild and did not affect treatment. No neurological adverse effect was reported. Neurological examinations revealed no abnormality in any patient after treatment. Seven volunteer subjects underwent medical, neurological and ophthalmological examinations, and electrophysiological studies of ulnar and peroneal nerve conduction before and after treatment with the drugs in therapeutic doses (study B). Transient paresthesias were reported by one subject on the fourth day of treatment. No medical, neurological or ophthalmological abnormality was detected in any subject after treatment. There was no significant change in motor nerve conduction velocities. There was a significant (P less than 0.001) increase in the stimulus strength for distal ulnar stimulation and a significant (P less than 0.01) decrease in stimulus duration for proximal and distal ulnar stimulation. No significant changes were seen in the peroneal nerves in these parameters. No qualitative abnormality was seen in the oscilloscopic patterns of nerve conduction after treatment. Literature on the neurotoxicity of the halogenated hydroxyquinolines is reviewed. It is concluded that broxyquinoline and brobenzoxaldine (and probably other halogenated hydroxyquinolines as well) are safe and effective in therapeutic doses; neurotoxicity is unlikely to occur when these drugs are used according to therapeutic recommendations.
Swain
R
R
Bapna
J S
JS
Das
A K
AK
Chandrasekar
S
S
Swaminathan
R P
RP
Bosco
B
B
Veliath
S
S
Thombre
D P
DP
D000328:Adult; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity; D004404:Dysentery, Amebic / Q000188:drug therapy; D005260:Female; D006356:Heartburn / Q000139:chemically induced; D006801:Humans; D006912:Hydroxyquinolines / Q000633:toxicity*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009422:Nervous System Diseases / Q000139:chemically induced*; D009431:Neural Conduction / Q000187:drug effects*; D015125:Oxyquinoline / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use / Q000633:toxicity*; D010292:Paresthesia / Q000139:chemically induced; D010543:Peroneal Nerve / Q000187:drug effects; D005082:Physical Exertion / Q000187:drug effects; D011446:Prospective Studies; D011537:Pruritus / Q000139:chemically induced; D011798:Quinaldines / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity*; D011804:Quinolines / Q000633:toxicity*; D014459:Ulnar Nerve / Q000187:drug effects
D004338:Drug Combinations; D006912:Hydroxyquinolines; D011798:Quinaldines; D011804:Quinolines; D015125:Oxyquinoline; C001454:brobenzoxaldine, broxyquinoline drug combination